Dr.ย Patrickย Wen
MBBS, Board Certified Neurology & Neuro-Oncology
Director, Center for Neuro-Oncology
corporate_fareDana-Farber Cancer Institute, Boston
Patrick Wen
MBBS, Board Certified Neurology & Neuro-Oncology
Dr. Patrick Y. Wen is Director of the Center for Neuro-Oncology at Dana-Farber Cancer Institute and Professor of Neurology at Harvard Medical School, where he has led brain tumour care and research for several decades. He also serves as Director of the Neuro-Oncology Division at Brigham and Women's Hospital and is a member of the Neuro-Oncology Program at Dana-Farber/Harvard Cancer Center.
Dr. Wen completed his medical training at the University of London and undertook residency through the Harvard / MGB Combined Training Programme, earning board certifications in both Neurology and Neuro-Oncology. His clinical practice focuses on adults with brain and spinal cord tumours, including glioma, glioblastoma, high-grade and low-grade gliomas, and leptomeningeal metastases. His research programme has explored gene therapy, inhibitors of angiogenesis, hormonal therapy, radionuclide-based strategies, and the neurological complications of cancer treatment. He is closely associated with the Response Assessment in Neuro-Oncology (RANO) framework and led the international effort to develop RANO 2.0, a unified set of criteria for assessing response and progression in adult gliomas across clinical trials.
CancerFax can coordinate medical-record review and consultation support for international patients seeking an opinion from Dr. Wen at Dana-Farber Cancer Institute, subject to hospital availability and case acceptance.
Why Consider Dr. Patrick Wen?
Dr. Wen brings more than four decades of neuro-oncology expertise, leading one of the world's foremost brain tumour programmes at a Harvard-affiliated cancer centre.
Areas of Specialisation
Adult brain and central nervous system tumour care, with a research focus on glioma and novel brain tumour therapies
Dr. Wen's clinical and research specialisation centres on adult neuro-oncology, encompassing primary brain tumours and neurological complications in cancer patients.
Glioma & Glioblastoma
Diagnosis, treatment planning, and clinical trial evaluation for adults with high-grade and low-grade gliomas.
- arrow_rightTreatment planning for newly diagnosed and recurrent glioblastoma
- arrow_rightAssessment of treatment response using RANO and RANO 2.0 criteria
- arrow_rightClinical trial options for eligible patients with recurrent high-grade glioma
- arrow_rightEvaluation of low-grade glioma behaviour and progression risk
- arrow_rightIndividualised treatment planning including observation, radiotherapy, and systemic therapy
Brain Tumour Clinical Trials & Novel Therapies
Active participation in clinical trial development for brain tumours and research into new treatment strategies.
- arrow_rightEvaluation of eligibility for brain tumour clinical trials at Dana-Farber
- arrow_rightPI3K/mTOR inhibitor trials for recurrent high-grade glioma
- arrow_rightAnti-angiogenic therapy research for brain tumours
- arrow_rightGene therapy and radionuclide-based therapeutic research
- arrow_rightHormonal and molecularly targeted approaches under investigation
Leptomeningeal Metastases & Neurological Complications
Specialist care for brain and spinal cord involvement from systemic cancers, and neurological complications arising during cancer treatment.
- arrow_rightDiagnosis and treatment planning for leptomeningeal spread of cancer
- arrow_rightEvaluation of systemic and intrathecal treatment options
- arrow_rightAssessment and management of nervous system complications arising from cancer or its treatment
Procedures & Clinical Services
Neuro-oncology evaluation, brain tumour treatment planning, and clinical trial coordination at Dana-Farber Cancer Institute
Dr. Wen provides specialist neuro-oncology evaluation and treatment planning within a multidisciplinary team setting, with access to active clinical trials for eligible patients.
Neuro-Oncology Evaluation & Treatment Planning
Medical OncologyComprehensive assessment and treatment planning for adults with brain and CNS tumours.
Systemic Brain Tumour Treatment
Targeted TherapySystemic therapy options for primary brain tumours, including targeted and experimental approaches.
Clinical Trial Participation
Complex DiseaseAccess to brain tumour clinical trials at Dana-Farber Cancer Institute for eligible patients.
Second Opinion โ Brain Tumour
Second OpinionExpert second-opinion review of brain tumour diagnosis, pathology, and treatment plan.
Multidisciplinary Brain Tumour Care
MultidisciplinaryCoordinated care within the Dana-Farber Center for Neuro-Oncology's specialist team.
Research & Publications
Contributions to glioma treatment science, clinical trial development, and international response assessment standards
Dr. Wen has contributed extensively to brain tumour research, with particular impact in glioma response assessment, targeted therapeutics, and clinical trial methodology.
Dr. Wen has authored and co-authored a substantial body of peer-reviewed neuro-oncology research. A full publication list is available via PubMed and Harvard Medical School faculty pages.
Education & Training
Dr. Wen trained in medicine at the University of London and undertook postgraduate neurology residencies in the United Kingdom before completing further residency training through the Harvard / MGB Combined Neurology Programme. He holds board certifications in Neurology and Neuro-Oncology.
Clinical Experience
Dr. Wen has spent his career at Dana-Farber Cancer Institute and Harvard Medical School, building and directing one of the United States' foremost neuro-oncology programmes.
Languages & International
Dr. Wen consults in English. Additional languages were not confirmed from public sources.
CancerFax can coordinate professional medical interpreter support for international patients seeking care at Dana-Farber Cancer Institute.
CancerFax can coordinate professional medical interpreter support for international patients when required.
How CancerFax Helps You Access Dr. Patrick Wen
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Patrick Wen's team โ with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history โ prepared as a structured clinical summary for Dr. Patrick Wen's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Patrick Wen before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Patrick Wen's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Patrick Wen's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Patrick Wen's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Dr. Patrick Wen
Dr. Patrick Wen specialises in adult neuro-oncology, with a particular focus on glioblastoma, high-grade and low-grade gliomas, brain and spinal cord tumours, and leptomeningeal metastases. He also manages neurological complications that arise during cancer treatment.
Dr. Wen is based at Dana-Farber Cancer Institute and Brigham and Women's Hospital in Boston, Massachusetts. He directs the Center for Neuro-Oncology at Dana-Farber and the Neuro-Oncology Division at Brigham and Women's Hospital, and holds a professorship at Harvard Medical School.
A second-opinion request for Dr. Wen can be submitted through CancerFax with the patient's MRI reports, pathology results, molecular tumour profiling, and current treatment history. The CancerFax team will prepare the case and coordinate the next steps with Dana-Farber Cancer Institute, subject to availability and case acceptance.
Submit your medical reports โ including MRI scans, pathology, and treatment records โ through the CancerFax upload portal. The CancerFax team will review the documents, prepare the case for submission, and coordinate with Dana-Farber Cancer Institute on the next steps, subject to the institution's availability.
Dana-Farber Cancer Institute treats patients from many countries. CancerFax can support international patients by coordinating report review and consultation pathways with the institution. Patients should contact CancerFax or Dana-Farber directly to confirm current international patient intake procedures.
RANO 2.0 is an updated international framework for assessing how well treatments are working in patients with adult gliomas โ both high-grade and low-grade. It standardises how oncologists and researchers measure tumour response and progression in clinical trials, which helps ensure that promising new treatments are evaluated accurately. Dr. Wen proposed and led the development of RANO 2.0 with an international team of neuro-oncologists and neuroradiologists.
Dana-Farber Cancer Institute runs active clinical trials in neuro-oncology, and Dr. Wen has been involved in trial development for brain tumours, including studies on targeted PI3K/mTOR inhibitors for recurrent high-grade glioma. CancerFax can help coordinate the inquiry process for international patients who wish to explore clinical trial eligibility, subject to Dana-Farber's intake criteria.
Connect with Patrick Wen Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.